scholarly journals Combination Immunotherapy with Cytotoxic T-Lymphocyte–Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis

2019 ◽  
Vol 19 (3) ◽  
pp. 802-811 ◽  
Author(s):  
Ting Sun ◽  
Wenjia Zhang ◽  
Yuan Li ◽  
Zhengyu Jin ◽  
Yang Du ◽  
...  
2020 ◽  
Vol 8 (2) ◽  
pp. 103-110
Author(s):  
Muhamad Addin Syakir ◽  
Dwi Indria Anggraini

Pendahulan: Imunoterapi untuk kanker digunakan berdasarkan prinsip penyakitnya bahwa sistem kekebalan tubuh mampu menghasilkan respons imun terhadap sel-sel tumor. Saat ini tatalaksana yang tersedia untuk pasien melanoma selektif berdasarkan tingkat respons dari penyakitnya. Tujuan: Untuk mengetahui tatalaksana melanoma yang menggunakan imunologi. Metode: Artikel ini disusun menggunakan metode literature review, menggunakan 32 sumber berasal dari jurnal dan buku. Hasil: Interferon-α telah disetujui untuk pengobatan ajuvan stadium III melanoma dengan peningkatan survival rate. Diperlukan pendekatan baru dan lebih inovatif dengan peningkatan efek terapi. Prognosis pasien dengan melanoma metastasis di dunia telah berubah secara dramatis sejak adanya imun checkpoint inhibitor. Pembahasan: Ipilimumab, yang menargetkan protein cytotoxic T lymphocyte-associated protein 4 (CTLA-4) adalah agen pertama yang ada. Selanjutnya nivolumab dan pembrolizumab yang berikatan dengan protein programmed death protein 1 (PD-1) telah terbukti lebih efektif dan lebih rendah angka toksisitasnya daripada ipilimumab. Kombinasi nivolumab atau pembrolizumab dengan ipilimumab telah menghasilkan peningkatan tingkat respons dan hasil survival rate pasien. Tinjauan pustaka ini akan mengeksplorasi data uji klinis penting yang telah menyebabkan penggunaan agen imunoterapi ini di dunia dan beberapa hasil uji klinis yang saat ini dilaporkan untuk terapi kombinasi baru. Simpulan: Saat ini terapi imunologi untuk tatalaksana melanoma dapat di terapkan.   Kata kunci: Imunoterapi, kemoterapi, melanoma, tatalaksana


2019 ◽  
Vol 87 (12) ◽  
Author(s):  
Anuradha Rajamanickam ◽  
Saravanan Munisankar ◽  
Chandrakumar Dolla ◽  
Thomas B. Nutman ◽  
Subash Babu

ABSTRACT Chronic helminth infections are known to be associated with the modulation of antigen-specific T-cell responses. Strongyloides stercoralis infection is characterized by the downmodulation of antigen-specific Th1 and Th17 responses and the upregulation of Th2 and Th9 responses. Immune homeostasis is partially maintained by negative regulators of T-cell activation, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1), which dampen effector responses during chronic infections. However, their roles in S. stercoralis infection are yet to be defined. Therefore, we sought to determine the role of CTLA-4 and PD-1 in regulating CD4+ and CD8+ T-cell responses and examined the frequencies of monofunctional and dual functional Th1/T cytotoxic type 1 (Tc1), Th17/Tc17, Th2/Tc2, and Th9/Tc9 cells in S. stercoralis infection in 15 infected individuals stimulated with parasite antigen following CTLA-4 or PD-1 blockade. Our data reveal that CTLA-4 or PD-1 blockade results in significantly enhanced frequencies of monofunctional and dual functional Th1/Tc1 and Th17/Tc17 cells and, in contrast, diminishes the frequencies of monofunctional and dual functional Th2/Tc2 and Th9/Tc9 cells with parasite antigen stimulation in whole-blood cultures. Thus, we demonstrate that CTLA-4 and PD-1 limit the induction of particular T-cell subsets in S. stercoralis infection, which suggests the importance of CTLA-4 and PD-1 in immune modulation in a chronic helminth infection.


2021 ◽  
Vol 93 (6) ◽  
pp. 649-660
Author(s):  
Elena S. Kamyshova ◽  
Irina N. Bobkova ◽  
Marina I. Sekacheva

Immune checkpoint inhibitors (ICIs), including cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) and programmed death protein 1 (PD-1) or its ligand (PD-L1), are a new generation of immuno-oncological drugs that to date have demonstrated efficacy in a number of malignancies. The mechanism of ICT inhibitors action consist in the potentiation of the immune response by eliminating the tumor cells inhibitory effect on the T-lymphocytes activation. However, excessive immune system activation can cause the development of a special class of immune-related adverse events (irAEs) involved a wide variety of organs and systems, including the kidneys. Despite the fact that immuno-mediated kidney injury caused by ICI therapy develops quite rarely, it can be serious and determine the patient's prognosis, which necessitates early diagnosis and timely start of treatment. In this regard, awareness of the manifestations of ICI-associated renal irAEs is particularly relevant not only for oncologists and for nephrologists, but for doctors of other specialties. In this review, we elucidated the main variants of immuno-mediated kidney injury caused by ICI therapy, discussed possible predictors and mechanisms of their development, and considers the general principles of diagnosis and management of patients according to the severity of irAEs.


2009 ◽  
Vol 83 (3) ◽  
pp. 289-294 ◽  
Author(s):  
Scherezade Momin ◽  
Sylvia Flores ◽  
Bárbara Angel B ◽  
Ethel Codner D ◽  
Elena Carrasco P ◽  
...  

2019 ◽  
Vol 6 (4) ◽  
pp. MMT30 ◽  
Author(s):  
Ester Simeone ◽  
Antonio M Grimaldi ◽  
Lucia Festino ◽  
Claudia Trojaniello ◽  
Maria G Vitale ◽  
...  

Checkpoint inhibitors can cause an imbalance in immune tolerance that may clinically manifest as immune-related adverse events (irAEs). These events may involve many organs and tissues, including the skin, gastrointestinal (GI) tract, liver, endocrine system, kidneys, central nervous system (CNS), eyes and lungs. The incidence of irAEs appears to be lower with anti-programmed death antigen-1/programmed death antigen-ligand-1 agents than with the anti-cytotoxic T-lymphocyte-associated protein-4 antibody ipilimumab. Combined immunotherapy does not appear to be associated with novel safety signals compared with monotherapy, but more organs may be involved. Increased experience and the use of algorithms for the most common irAEs have resulted in severe toxicity and related deaths being reduced. However, continuous vigilance, especially regarding less common events, is needed to better characterize the wide spectrum of clinical manifestations.


Sign in / Sign up

Export Citation Format

Share Document